Home  
  Our Team  
  Patient Info  
  Services  
   
  Pay My Bill  
  Contact Us  

News for Healthier Living

Phase 3 Study: New Therapy Keeps Gastrointestinal Cancer Care on Course When Low Platelets Are an Obstacle

A phase 3 trial in NEJM shows the drug romiplostim can help gastrointestinal cancer patients stay on schedule with chemotherapy despite low platelet counts. In the RECITE study, 84% of patients receiving the drug avoided dose delays or reductions, compared with 36% on placebo--suggesting a new way to prevent a common treatment disruption.

March 17, 2026


March 17 2026

March 16 2026

March 15 2026

March 14 2026

March 13 2026

March 12 2026

March 11 2026

March 10 2026

March 9 2026

March 8 2026

March 7 2026

March 6 2026

March 5 2026

March 4 2026

March 3 2026